Market Overview

Jefferies Raises PT On Amgen, Pricing Pressure Factored IN

Share:
Related AMGN
Short Sellers Come Back To Biotech Stocks
Evercore ISI Technical Analysis: The 'Single Best Idea'
Amgen: The Best Biotech Stock You Don't Own (Seeking Alpha)

Analysts at Jefferies on Friday, March 28, 2014, released a new price target regarding Amgen (NASDAQ: AMGN).

Equity analyst Eun K. Yang at Jefferies led the research and raised their price target from $138.00 to $145.00 per share.

From the 48 cardiologists' surveys taken, Jefferies is increasing its United States and European Union sales estimates for 2017-2020 by 22 to 49 percent. According to Jefferies, this new estimate reflects its broad use in hypercholesterolemia.

Jefferies now estimates sales to be at approximately $1.7 billion in 2019, this is up $0.5 billion from its estimate of $1.2 billion.

The price target issued by Jefferies is based on:

• P/E multiple of ~16x (2015 P/E for big pharma) to our 2015 EPS forecast of $9.26, discounting at 10 percent. • Sum-of-the parts NPV analysis. Risks associated with Amgen include pricing pressure, competition and regulatory delays/failure of evolocumab (AMG-145)

Shares of Amgen are currently trading at $120.55 as of Friday, March 28, 2014.

Latest Ratings for AMGN

DateFirmActionFromTo
Jan 2015BarclaysInitiates Coverage onEqual-weight
Jan 2015Morgan StanleyDowngradesOverweightEqualweight
Oct 2014CitigroupMaintainsBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Eun K. Yang JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→